Veracyte Beats Q2 Revenue, Lifts 2026 Guidance on Robust Test Growth
VCYT has more than doubled off its 52-week low of $22.92.
Summary
Veracyte posted Q2 2026 revenue of $150.3M, up 15% YoY and ahead of estimates, and raised full-year revenue guidance to $590M–$596M. The beat was driven by strong test volume growth and new product launches.
Key Events · Earnings and Guidance · VCYT
-
Q2 Revenue Beats, Up 15% YoY
Total revenue of $150.3M exceeded consensus by ~4%, driven by 20% growth in Decipher and 18% growth in Afirma testing revenue.
-
Full-Year Guidance Raised
2026 total revenue guidance raised to $590M-$596M (14-15% growth) from prior $582M-$592M, with testing revenue guidance raised to $576M-$582M (17-18% growth).
-
Profitability Improves
GAAP net income of $25.5M ($0.31 diluted EPS) vs. a loss of $1.0M a year ago; adjusted EBITDA of $44.0M (29.2% margin) vs. $35.8M (27.5% margin).
-
New Product Launches Expand TAM
Launched Prosigna LDT for breast cancer and TrueMRD for muscle-invasive bladder cancer; secured Medicare coverage for TrueMRD, the first for the whole-genome sequencing platform.
Analysis · VCYT · Industrial Applications And Services
A strong second quarter saw revenue reach $150.3M, beating consensus by roughly 4% and climbing 15% year-over-year. The outperformance was fueled by a 20% surge in Decipher and an 18% advance in Afirma. Bolstered by new product launches and sustained demand, management raised full-year revenue guidance to $590M–$596M. Profitability also strengthened, with GAAP net income hitting $25.5M and adjusted EBITDA margin expanding to 29.2%. The launch of Prosigna LDT and TrueMRD, together with Medicare coverage for TrueMRD, widens the addressable market and underpins the upgraded outlook.
At the time of this filing, VCYT was trading at $55.11 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $4.8B. The 52-week trading range was $22.92 to $60.91. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.